BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 29364867)

  • 21. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
    Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
    Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
    Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
    Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.
    Morton JP; Jamieson NB; Karim SA; Athineos D; Ridgway RA; Nixon C; McKay CJ; Carter R; Brunton VG; Frame MC; Ashworth A; Oien KA; Evans TR; Sansom OJ
    Gastroenterology; 2010 Aug; 139(2):586-97, 597.e1-6. PubMed ID: 20452353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.
    Lee KE; Bar-Sagi D
    Cancer Cell; 2010 Nov; 18(5):448-58. PubMed ID: 21075310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
    Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
    Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
    Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
    Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
    Genovese G; Carugo A; Tepper J; Robinson FS; Li L; Svelto M; Nezi L; Corti D; Minelli R; Pettazzoni P; Gutschner T; Wu CC; Seth S; Akdemir KC; Leo E; Amin S; Molin MD; Ying H; Kwong LN; Colla S; Takahashi K; Ghosh P; Giuliani V; Muller F; Dey P; Jiang S; Garvey J; Liu CG; Zhang J; Heffernan TP; Toniatti C; Fleming JB; Goggins MG; Wood LD; Sgambato A; Agaimy A; Maitra A; Roberts CW; Wang H; Viale A; DePinho RA; Draetta GF; Chin L
    Nature; 2017 Feb; 542(7641):362-366. PubMed ID: 28178232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.
    Eibl G; Rozengurt E
    Semin Cancer Biol; 2019 Feb; 54():50-62. PubMed ID: 29079305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
    Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
    Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
    Agrawal R; Natarajan KN
    Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.
    Cano CE; Hamidi T; Garcia MN; Grasso D; Loncle C; Garcia S; Calvo E; Lomberk G; Dusetti N; Bartholin L; Urrutia R; Iovanna JL
    Gut; 2014 Jun; 63(6):984-95. PubMed ID: 24026351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.